Akebia Therapeutics, Inc.
AKBA · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $722,867 | $955,738 | $452,156 | $415,528 |
| - Cash | $166,444 | $137,308 | $113,374 | $51,870 |
| + Debt | $213,294 | $53,362 | $54,148 | $47,640 |
| Enterprise Value | $769,717 | $871,792 | $392,930 | $411,298 |
| Revenue | $58,766 | $62,472 | $57,336 | $46,497 |
| % Growth | -5.9% | 9% | 23.3% | – |
| Gross Profit | $49,065 | $52,553 | $49,711 | $26,132 |
| % Margin | 83.5% | 84.1% | 86.7% | 56.2% |
| EBITDA | $6,221 | $7,397 | $14,196 | -$6,582 |
| % Margin | 10.6% | 11.8% | 24.8% | -14.2% |
| Net Income | $540 | $247 | $6,112 | -$22,804 |
| % Margin | 0.9% | 0.4% | 10.7% | -49% |
| EPS Diluted | 0.002 | 0.001 | 0.025 | -0.1 |
| % Growth | 122.2% | -96.4% | 125.3% | – |
| Operating Cash Flow | $28,105 | $22,345 | -$13,587 | -$4,466 |
| Capital Expenditures | -$77 | -$126 | -$18 | -$2 |
| Free Cash Flow | $28,028 | $22,219 | -$13,605 | -$4,468 |